## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.1% below STRENGTH zone (4.0-10.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 1)

**1. Is Abbott Laboratories Still Attractively Priced After Recent Medical Device Momentum In 2025?**
- Source: Simply Wall Street | 20251217T230917 | Somewhat-Bearish | Relevance: 100%
- Abbott Laboratories (ABT) is currently trading around $126 a share, with recent momentum driven by its medical devices and diagnostics portfolio. While a Discounted Cash Flow (DCF) analysis suggests the stock is 72.7% overvalued, its Price-to-Earnings (PE) ratio of 15.8x is significantly below the Medical Equipment industry average, indicating it might be undervalued based on earnings. Simply Wall St's proprietary Fair Ratio for Abbott is 25.6x, further supporting an "undervalued" assessment on an earnings basis.

**2. Is Abbott Laboratories Still Attractively Priced After Recent Medical Device Momentum In 2025?**
- Source: Simply Wall Street | 20251217T224303 | Neutral | Relevance: 100%
- Abbott Laboratories (NYSE: ABT) has seen recent stock momentum, with a 15.3% return over the last year. While a Discounted Cash Flow (DCF) analysis suggests it might be overvalued by 72.7% at its current share price of $126, its Price-to-Earnings (PE) ratio of 15.8x is significantly below the industry average, indicating it could be undervalued based on earnings. The article also introduces "Narratives" as a way for investors to create dynamic valuations based on different future outlooks for the company.

**3. Nilsine Partners LLC Cuts Stake in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251217T111949 | Somewhat-Bullish | Relevance: 100%
- Nilsine Partners LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 46.5% during the third quarter, selling 11,583 shares and retaining 13,316 shares valued at $1.784 million. This comes as Abbott reported Q3 EPS of $1.30, in line with estimates, and revenue of $11.37 billion, slightly below expectations, while also raising its quarterly dividend to $0.63 per share. Several analysts maintain positive ratings on ABT, with an average price target of $147.00.

**4. Insight Wealth Strategies LLC Invests $4.91 Million in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251216T134407 | Bullish | Relevance: 100%
- Insight Wealth Strategies LLC initiated a new position in Abbott Laboratories (NYSE:ABT) during the third quarter, acquiring 36,673 shares valued at approximately $4.91 million. Abbott Laboratories recently reported Q3 EPS of $1.30 and revenue of $11.37 billion, and has raised its quarterly dividend to $0.63, reflecting a "Moderate Buy" consensus rating among analysts with a price target of $147.00. Institutional investors collectively own about 75% of the shares in the company.

**5. Union Bancaire Privee UBP SA Sells 20,132 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20251217T141053 | Somewhat-Bullish | Relevance: 100%
- Union Bancaire Privee UBP SA reduced its stake in Abbott Laboratories by selling 20,132 shares, bringing its total holdings to 200,289 shares valued at $26.83 million. Abbott reported Q3 EPS of $1.30, in line with estimates, and revenue of $11.37 billion, slightly below consensus, while also raising its quarterly dividend to $0.63. The stock holds a "Moderate Buy" consensus rating from analysts with an average price target of $147.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.12M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.0x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.8B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.0 |
| Current P/E | 24.3 |
| YoY Growth | 10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.1% to 0.1% (+1.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 47. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.08% (CS: 41) | Neutral |
| RSI_14 | 46.8 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 0.985x | Below |
| vs SMA200 | 0.960x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.08
- **Stop Loss:** $120.02 (4.0% risk)
- **Target:** $130.14 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 187
- **Position Value:** $23,389.96
- **Portfolio %:** 23.39%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*